

RIGImmune Acquires Subintro

Client News

September 15, 2022

Gunderson Dettmer represented client RIGImmune, a biopharmaceutical company developing a new class of RNA immunotherapeutics, in its acquisition of Subintro, a biotechnology company specializing in the development and delivery of antiviral therapeutics for respiratory diseases caused by RNA viruses. The newly combined company will work to further advance novel compounds that both activate the natural immune activation and demonstrate antiviral activity.

In the [announcement of the acquisition](#), President of RIGImmune Susan Sobolov said, “Joining with the experienced Subintro team will allow us to further advance our development of new treatments, prophylactics and vaccine adjuvants for respiratory diseases caused by RNA viruses. By combining our stem-loop RNA therapeutics or “SLRs” with the Subintro antivirals and novel topical delivery systems, we aim to achieve optimal management of viral respiratory diseases.”

The Gunderson Dettmer deal team was led by Tim Ehrlich and included Tim Kulis and Annie Cho.

Companies

[RIGImmune](#)

Related People





Timothy H. Ehrlich

PARTNER

P +1 617 648 9399

Timothy J. Kulis

PARTNER-ELECT

P +1 617 648 9236

Related Services

Late-Stage Company

Mergers & Acquisitions

Featured Insights

PUBLIC VENTURES

Trump Executive Order Targets Proxy Advisors Over DEI and ESG Influence

EVENTS

Webinar: Paradigm Shift? Mandatory Securities Arbitration and the Impact of the SEC's Recent Policy Statement for Companies and Investors

FIRM NEWS

Amidst Strong Year, Gunderson Dettmer Elects Nine New Partners

EVENTS

Webinar: AI in the Workplace: Legal Challenges and Best Practices

FIRM NEWS

2025 CVCA Annual General Meeting & Private/Venture Capital Summit in Beijing

CLIENT NEWS

Gunderson Dettmer Represented Hims & Hers in Acquisition of Livewell

CLIENT NEWS

Replicate Bioscience Announces Collaborative Agreement with Instituto Butantan

CLIENT NEWS

Gunderson Client Neptune to Be Acquired by OpenAI

CLIENT NEWS

Hims & Hers Announces Definitive Agreement to Acquire YourBio Health

CLIENT NEWS

LotusFlare Announces Equity Investment from Ericsson

PUBLIC VENTURES

SEC Chair Charts Disclosure Overhaul to Revive IPOs: Materiality and Scale Over 'Regulatory Creep'

CLIENT NEWS

Vambe Raises \$14M Series A Led by Monashees